U.S. Luxury Stock News

Wondering whether CubeSmart's current share price still offers value, or if most of the opportunity has already been priced in? This article breaks down what the numbers actually say about the stock. CUBE has had a mixed run recently, with a 3.4% decline over 7 days, a 12.7% decline over 30 days, a 1.4% gain year to date, and an 11.4% decline over the last year, which can change how the market views its risk and return profile. Recent coverage has focused on CubeSmart's share price moves and...

DTE Energy (DTE) drew fresh attention after its recent trading session, with the stock closing at $146.06 and short term returns showing mixed moves over the past week, month and past 3 months. See our latest analysis for DTE Energy. Looking beyond the latest move, DTE Energy’s share price return of 12.0% year to date and 12.5% over 90 days points to building momentum. The 1 year total shareholder return of 9.2% and 3 year total shareholder return of 48.6% reflect a solid longer term outcome...

Home Depot (NYSE:HD) has appointed Dr. Franziska "Fran" Bell as executive vice president and chief technology officer. Dr. Bell will lead enterprise-wide technology, digital product management, and AI efforts for the company. She brings experience from senior technology and AI roles at Ford, BP, and Uber. Home Depot, a major home improvement retailer serving DIY customers and professionals, is moving further toward tech-driven retail operations with this leadership change. Retailers...

StepStone Group (STEP) is back on investor screens after recent share price swings, with the stock up over the past month but lower across the past 3 months and year to date. See our latest analysis for StepStone Group. The recent rebound, including a 7.81% 1 month share price return from a last close of US$46.51, comes after a much weaker 90 day share price return of a 27.99% decline. The 3 year total shareholder return of 114.48% contrasts with a 1 year total shareholder return of an 8.57%...

Abbott Laboratories is integrating its Precision Oncology portfolio into Flatiron Health's OncoEMR platform used by a wide U.S. oncology network. The move brings Abbott's advanced cancer diagnostics directly into clinicians' electronic workflows, aiming to simplify ordering and results review. This development follows Abbott's expansion into cancer diagnostics through its deal with Exact Sciences. For investors tracking NYSE:ABT, this news sits against a mixed share price picture. The stock...

Wondering if DRDGOLD at around US$27.65 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price might imply. The stock has returned 1.7% over the last 7 days, while the 30 day return sits at a 28.9% decline, against an 8.8% decline year to date and an 81.5% return over the past year, with a very large 3 year and 226.1% 5 year return. Recent coverage has focused on DRDGOLD as part of broader gold and precious metals...

In March 2026, Academy Sports and Outdoors, Inc. reported fourth-quarter sales of US$1,718.47 million and net income of US$133.69 million, issued full-year 2027 guidance, and confirmed completion of a share repurchase program totaling 5,089,876 shares for US$263.51 million. While full-year sales edged up to US$6,053.41 million but net income softened to US$376.77 million, the combination of higher fourth-quarter earnings per share and ongoing buybacks highlights how capital allocation and...

If you are looking at Halozyme Therapeutics and wondering whether the current share price reflects its true worth, this breakdown will help you make sense of what you are paying for. The stock recently closed at US$62.13, with returns of 1.2% decline over 7 days, 10.6% decline over 30 days, 11.6% decline year to date and 2.6% decline over 1 year, set against gains of 60.4% over 3 years and 44.7% over 5 years. Recent coverage has focused on how the share price has moved over different time...

Recently, BioMarin Pharmaceutical discontinued three Phase 2 Voxzogo studies following safety concerns, while simultaneously reporting encouraging clinical and real-world outcomes for the drug in other settings. The company and analysts now suggest that Voxzogo’s safety issues may be limited to specific uses, with BioMarin’s broader outlook increasingly supported by its wider rare-disease portfolio. Now we’ll explore how the Voxzogo safety-driven trial discontinuations, alongside positive...

CIM Real Estate Finance Trust (OTCPK:CMRF) has wrapped up FY 2025 with fourth quarter revenue of US$97.9 million and basic EPS of US$0.07, giving investors a clean snapshot of how the year finished. Over recent periods, revenue has shifted from US$121.4 million in Q3 2024 to US$106.2 million in Q4 2024, then to US$106.4 million in Q1 2025, US$107.2 million in Q2 2025, US$104.5 million in Q3 2025 and US$97.9 million in Q4 2025, while quarterly EPS moved from US$0.02 to an interim loss before...

This article examines whether Compass at US$6.84 may represent attractive value or a potential value trap by exploring what the current price could be implying about the business. The stock has come under pressure recently, with a 19.2% decline over the last 7 days, 29.8% over 30 days, 34.9% year to date, and 21.6% over the past year, following a very large 3-year gain of 110.5% and a 5-year decline of 63.2%. Recent coverage has highlighted Compass as a real estate platform operating in a...

If you are wondering whether Roku's current share price reflects its true worth, you are not alone; the stock's recent moves have raised fresh questions about what you are really paying for. Roku closed at US$88.23, with returns of a 9.8% decline over 7 days, a 10.3% decline over 30 days and an 18.8% decline year to date, set against a 25.3% gain over 1 year and 34.3% over 3 years, while the 5 year return stands at a 73.1% decline. Recent headlines around Roku have focused on its position in...

If you are wondering whether Alphatec Holdings at around US$11 is a bargain or a value trap, the key is to look past the headline share price and into how it stacks up on valuation. The stock has seen a 9.5% decline over the last week, a 19.2% decline over the last 30 days, and is down 47.0% year to date, even though the 1 year return sits at 8.5%. These moves sit against a backdrop of ongoing interest in medical equipment companies, with investors weighing up growth potential in specialist...

Box (BOX) has expanded its equity buyback plan, adding US$500 million in authorization to reach US$1.86b and extending the program through September 30, 2027. This move refocuses attention on capital returns. See our latest analysis for Box. At a share price of US$23.32, Box has a 90 day share price return of 23.31% and a one year total shareholder return of 24.43% decline, pointing to fading momentum even as the larger buyback program draws fresh attention from investors. If you are weighing...

Wondering if Bristol-Myers Squibb at around US$59.73 is a bargain or a value trap? This article walks through the key signals that matter for you as a shareholder or potential investor. The stock is up 4.8% over the last week and 11.7% year to date. However, the 30-day return is a 4.2% decline and the one-year return sits at 2.9%, with a three-year return of a 1.7% decline and a five-year return of 14.4%. Recent attention on large pharmaceutical names, including Bristol-Myers Squibb, has...

If you are wondering whether XPeng's share price reflects its real worth, or if the market is mispricing the story, this article walks you through what the numbers are actually saying. XPeng's stock last closed at US$16.72, with returns of an 11.4% decline over 7 days, 4.8% decline over 30 days, 18.2% decline year to date and 19.3% decline over 1 year, set against a 52.0% gain over 3 years and 53.6% decline over 5 years. These mixed returns sit against a backdrop of ongoing headlines about...

Telesat (TSAT) stock has drawn attention after recent trading, with a 1 day return of about negative 9% and a 7 day move around negative 17%, following a strong past year and past 3 months. See our latest analysis for Telesat. Despite the recent pullback, with a 1 day share price return of negative 9.15% and a 7 day share price return of negative 17.34%, Telesat still shows stronger momentum over longer periods. This includes a 1 year total shareholder return of 78.70% and a 3 year total...

We wouldn't blame Hewlett Packard Enterprise Company ( NYSE:HPE ) shareholders if they were a little worried about the...

Investors were underwhelmed by the solid earnings posted by Kanzhun Limited ( NASDAQ:BZ ) recently. We did some digging...

Rising geopolitical tensions linked to the Iran war are raising fresh concerns about semiconductor supply chains. Helium, a key material for chip manufacturing, is in focus as potential disruption risks resurface. KLA Corporation (NasdaqGS:KLAC), a major supplier of process control and metrology tools to chip fabs, sits close to these supply chain fault lines. KLA earns much of its business from equipment and services that depend on stable fab activity and access to advanced materials such...

Nebius Group (NasdaqGS:NBIS) has agreed a multibillion dollar AI infrastructure deal with Meta Platforms, with the contract value exceeding Nebius's prior valuation. The company has also secured a $2b investment and an expanded partnership with Nvidia focused on advanced AI compute. Nebius plans to build one of Europe's largest AI data centres in Finland as part of its capacity expansion. Nebius Group operates in the AI cloud infrastructure space, supplying high end computing capacity to...

Voyager Technologies (VOYG) has drawn investor attention after posting annual revenue of US$166.419 million alongside a net loss of US$116.072 million, raising fresh questions about how its defense and space businesses are being valued. See our latest analysis for Voyager Technologies. The recent earnings update has coincided with a 7 day share price return of 21.54% decline and a year to date share price return of 21.06% decline, suggesting momentum has weakened despite earlier optimism...

If you are wondering whether Booz Allen Hamilton Holding is attractively priced right now or if the recent share level is hard to justify, this breakdown focuses squarely on what you are getting for the price you pay. The stock last closed at US$78.95, with returns of a 1.2% decline over 7 days, 0.2% over 30 days, and year-to-date and 1-year returns of a 7.0% decline and 22.6% decline. These figures may prompt questions about whether sentiment or valuation has shifted too far. Recent news...

MoonLake Immunotherapeutics: recent stock performance snapshot MoonLake Immunotherapeutics (MLTX) has seen mixed trading moves recently, with the stock down 2.3% over the past day and roughly 3.3% over the past month, while showing a gain of about 28% in the past 3 months. See our latest analysis for MoonLake Immunotherapeutics. The current share price of $16.93 sits alongside a 90 day share price return of 28.45% and a year to date share price return of 41.67%. In contrast, the 1 year total...